Citadel Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Citadel Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-37,700	Closed	-$174K	–	10297
2019 Q1	$174K	Sell	37,700 -10,300	-21%	-$48.8K	﹤0.01%	8301
2018 Q4	$168K	Sell	48,000 -32,300	-40%	-$224K	﹤0.01%	7991
2018 Q3	$809K	Buy	80,300 +21,500	+37%	+$172K	﹤0.01%	5910
2018 Q2	$426K	Buy	58,800 +47,400	+416%	+$331K	﹤0.01%	6639
2018 Q1	$69K	Sell	11,400 -28,000	-71%	-$231K	﹤0.01%	7839
2017 Q4	$379K	Buy	39,400 +16,300	+71%	+$107K	﹤0.01%	6086
2017 Q3	$205K	Sell	23,100 -30,000	-56%	-$310K	﹤0.01%	6662
2017 Q2	$672K	Sell	53,100 -17,000	-24%	-$201K	﹤0.01%	4697
2017 Q1	$737K	Buy	70,100 +32,400	+86%	+$345K	﹤0.01%	4456
2016 Q4	$347K	Buy	37,700 +11,400	+43%	+$129K	﹤0.01%	5471
2016 Q3	$310K	Buy	26,300 +14,500	+123%	+$220K	﹤0.01%	5627
2016 Q2	$153K	Buy	11,800 +700	+6%	+$10.2K	﹤0.01%	6016
2016 Q1	$177K	Sell	11,100 -34,700	-76%	-$659K	﹤0.01%	5727
2015 Q4	$1.31M	Buy	45,800 +24,200	+112%	+$670K	﹤0.01%	3258
2015 Q3	$615K	Sell	21,600 -31,500	-59%	-$1.16M	﹤0.01%	4502
2015 Q2	$1.91M	Buy	53,100 +15,300	+40%	+$477K	﹤0.01%	3112
2015 Q1	$1.1M	Buy	37,800 +12,200	+48%	+$323K	﹤0.01%	3808
2014 Q4	$540K	Sell	25,600 -1,000	-4%	-$19.8K	﹤0.01%	4626
2014 Q3	$516K	Buy	26,600 +16,200	+156%	+$254K	﹤0.01%	4575
2014 Q2	$162K	Buy	+10,400	New	+$168K	﹤0.01%	5799

Other funds holding INSY

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors's INSY Position: Q2 2019 in Review

Citadel Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 101,329 shares — an estimated $468K sold.

Citadel Advisors first reported a position in INSY in Q3 2013 and held it in 18 quarters. The position peaked at $27.5M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

Citadel Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Citadel Advisors sold 101,329 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $468K.
Citadel Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 18 quarters.
Citadel Advisors's Insys Therapeutics, Inc. position peaked at $27.5M in Q3 2015.
16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.